“These tumours are ultra rare, and it is simply not feasible to run a clinical trial involving hundreds of patients,” says Vivien Wong, executive vice president of R&D at Progenics ...

Melinta Therapeutics, LLC ("Melinta"), a commercial-stage company providing innovative therapies for acute and ...

Curium, a world leader in nuclear medicine, today announced that in Spain, PYLCLARI® is now available for patients with ...

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE:BMR) announced today that it has entered into a new ten-year lease with Progenics ...

Lantheus Holdings, Inc. is the parent company of Lantheus Medical Imaging, Inc., Progenics Pharmaceuticals, Inc. and EXINI Diagnostics AB and an established leader and fully integrated provider of ...

His non-academic experiences include working for Goldman, Sachs & Co., being the President of Progenics Pharmaceuticals, Inc. a start-up biotechnology company, and being the director of economics for ...

He began by highlighting the recent FDA approvals of Ga-68 gozetotide at UCLA and UCSF in December 2020 which were followed quickly by approval of piflufolastat F-18 from Progenics Pharmaceuticals in ...

If you are the provider of this service, resources on this page help you meet your legal duty to display your rating. These resources are the widget, which enables you to display the rating on your ...

PYLARIFY PET Imaging: A Transformative Resource for Urologists and Radiologists - Michael Kipper PSMA PET/CT Imaging Indications in Prostate Cancer - Neal Shore & Oliver Sartor NCCN Guidelines Update ...

Multivalent presentation of viral glycoproteins can substantially increase the elicitation of antigen-specific antibodies. To enable a new generation of anti-viral vaccines, we designed ...

Lymphocyte Infiltration Score and Spatial Characteristics Refined the Prognosis and Denosumab Treatment Responsiveness Indicators for Giant Cell Tumor of Bone Outcomes data for DNA-damaging ...

Molecular Insight was subsequently acquired by Progenics in 2013, who oversaw the completion of clinical testing and development of the drug. Unlike LSA-MIBG, HSA-MIBG was subjected to the ...